X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MaaT013 is a full-ecosystem, off-the-shelf, standardized, pooled-donor, enema Microbiome Ecosystem TherapyTM for acute, hospital use. It is being evaluated in combination with Ipilimumab for the treatment of metastatic melanoma.
Lead Product(s): MaaT013,Ipilimumab,Nivolumab
Therapeutic Area: Oncology Product Name: MaaT013
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
MaaT033 is a an oral, donor-derived, standardized, high-richness, high-diversity microbiome ecosystem therapies, for ambulatory use, containing Butycore. It is being evaluated for the treatment of amyotrophic lateral sclerosis.
Lead Product(s): MaaT033
Therapeutic Area: Neurology Product Name: MaaT033
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
The funding will be used forcompany's Phase 2b, evaluating MaaT033, an oral, donor-derived, standardized, high-richness, high-diversity microbiome ecosystem therapy, to improve overall survival for patients receiving second allogeneic stem cell transplantation (allo-HSCT2).
Lead Product(s): MaaT033
Therapeutic Area: Oncology Product Name: MaaT033
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bpifrance
Deal Size: $8.0 million Upfront Cash: Undisclosed
Deal Type: Funding November 30, 2023
Details:
MaaT033 is an allo-HCT, oral, donor-derived, standardized, high-richness, high-diversity microbiome ecosystem therapies, which is investigated for the treatment of patients undergoing Hematopoietic Stem Cell transplantation.
Lead Product(s): MaaT033
Therapeutic Area: Immunology Product Name: MaaT033
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2023
Details:
MaaT013 contains butycore which aims to restore the symbiotic relationship between the patient’s functional gut microbiome and their immune system to correct the responsiveness and tolerance of immune functions and reduce steroid-resistant, gastrointestinal-predominant aGvHD.
Lead Product(s): MaaT013
Therapeutic Area: Immunology Product Name: MaaT013
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2023
Details:
MaaT033 is an allo-HCT, oral, donor-derived, standardized, high-richness, high-diversity microbiome ecosystem therapies, which is investigated for the treatment of patients undergoing Hematopoietic Stem Cell transplantation.
Lead Product(s): MaaT033
Therapeutic Area: Immunology Product Name: MaaT033
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Details:
MaaT013 contains butycore which aims to restore the symbiotic relationship between the patient’s functional gut microbiome and their immune system to correct the responsiveness and tolerance of immune functions and reduce steroid-resistant, gastrointestinal-predominant aGvHD.
Lead Product(s): MaaT013
Therapeutic Area: Immunology Product Name: MaaT013
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2023
Details:
MaaT033 is an allo-HCT, oral, donor-derived, standardized, high-richness, high-diversity microbiome ecosystem therapies, for ambulatory use, containing Butycore , a group of bacterial species known to produce anti-inflammatory short-chain-fatty acid.
Lead Product(s): MaaT033
Therapeutic Area: Neurology Product Name: MaaT033
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2023
Details:
MaaT013 contains butycore which aims to restore the symbiotic relationship between the patient’s functional gut microbiome and their immune system to correct the responsiveness and tolerance of immune functions and reduce steroid-resistant, gastrointestinal-predominant aGvHD.
Lead Product(s): MaaT013
Therapeutic Area: Immunology Product Name: MaaT013
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 03, 2023
Details:
MaaT013 is a donor-derived, standardized, high-richness, high-diversity microbiome ecosystem therapy, containing ButycoreTM , a group of bacterial species known to produce anti-inflammatory short-chain-fatty acids.
Lead Product(s): MaaT013
Therapeutic Area: Immunology Product Name: MaaT013
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
